BIA
TLX

Bell Investment Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Bell Investment Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$808 Hold
70
– – ﹤0.01% 1593
2026
Q1 		$670 Buy
+70
New +$533 ﹤0.01% 1642

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Bell Investment Advisors's TLX Position: Q2 2026 in Review

Bell Investment Advisors held its Telix Pharmaceuticals (TLX) position steady in Q2 2026 at 70 shares worth $808. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Bell Investment Advisors first reported a position in TLX in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Bell Investment Advisors held 70 shares of Telix Pharmaceuticals worth $808 as of Q2 2026.
  • Bell Investment Advisors left its Telix Pharmaceuticals share count unchanged in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1593 holding.
  • Bell Investment Advisors first reported a position in Telix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.